/

NEO

NeoGenomics, Inc.Pre-market

16.20−0.15 −0.92%USD

NasdaqCM · as of Oct 12, 16:00 ET · 15m delayPre-market 16.11 −0.56%

Open

16.35

Prev close

16.35

Day range

15.8616.35

52-week range

7.0720.15

Volume

1.18M0.50×

Mkt cap

2.08B

P/E ttm

—

Fwd P/E

47.77

EPS ttm

-0.3900

Div yield

0.00%

Earnings

Jul 28, 2026

From 52w high

−19.60%

Price Chart

Yahoo Finance · delayed

NEOOct 12, 2026O 16.35H 16.35L 15.86C 16.20−0.15 (−0.92%)Vol 1.18M

SMA 5017.47
SMA 20012.47

1Y change +78.02% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

NEO NeoGenomics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −15.32%
1 month: −6.47%
3 months: +14.81%
6 months: +102.50%
Year to date: +37.76%
1 year: +78.02%

Valuation & ownership

Market cap: 2.08B
Enterprise value: 2.38B
P/E (ttm): —
Forward P/E: 47.77
PEG ratio: 2.09
Price / book: 2.64
Price / sales (ttm): 2.72
EV / EBITDA: 98.01
EPS (ttm): -0.3900
EPS (forward): 0.3391
Beta (5y monthly): 1.78
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 128.48M
Float: 116.97M
Short % of float: 13.00%
Short ratio (days): 6.99
Held by insiders: 2.11%
Held by institutions: 115.18%
Avg volume (3m): 2.39M
50-day average: 17.47
200-day average: 12.47
52-week change: +78.02%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 39.6
vs 50-day SMA: −7.27%
vs 200-day SMA: +29.94%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.87%
Realised vol (20d, ann.): 69.9%
From 52-week high: −19.60%
From 52-week low: +129.14%

ANR

Analyst Consensus

10 analysts

Consensus

Buy

1.67 on a 1 (strong buy) – 5 (sell) scale

Mean target

21.55

+33.02% implied

Low 16.00Median 20.00High 35.00

Recommendation trend

Now9 / 3 / 0
1m ago / 4 /

DES

About NeoGenomics, Inc.

Yahoo Finance profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2,500
Headquarters: Fort Myers, FL, United States
Website: neogenomics.com
Officers: Mr. Anthony P. Zook CEO & Director

SEAS

Seasonality · NEO

2007–2026 · monthly returns

Strongest month Jul +7.23%Weakest month Dec −3.79%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	2.6	-18.5	-24.5	24.8	13.6	38.7	4.8	17.1	2.5	-11.8			+37.8%
2025	-13.2	-30.1	-5.0	-32.6	13.8	0.4	-33.8	81.4	-12.1	26.6	23.8	-2.8	−28.6%
2024	-8.2	5.1	0.8	-11.5	-1.5	1.2	27.8	-6.8	-10.7	-7.9	30.5	-7.1	+1.9%
2023	28.6	41.8	3.3	-16.0	17.5	-6.5	7.8	-13.3	-18.2	14.0	29.6	-11.0	+75.1%
2022	-33.9	-5.0	-43.3	-22.2	-10.9	-3.2	24.2	-0.7	-14.3	-11.6	47.3	-17.6	−72.9%
2021	-1.5	-3.9	-5.4	1.6	-16.2	10.1	2.1	5.5	-0.8	-4.6	-25.5	-0.4	−36.6%
2020	10.2	-12.1	-2.5	-1.0	-2.4	16.1	23.4	1.9	-5.3	6.3	21.3	13.2	+84.1%
2019	31.8	17.9	4.4	1.8	4.2	1.1	11.1	2.5	-23.5	19.9	12.6	13.3	+132.0%
2018	-12.9	8.8	-2.9	17.4	21.1	13.0	6.8	-1.1	10.8	20.1	-11.1	-23.1	+42.3%
2017	-6.0	0.1	-2.2	-4.3	0.1	18.5	5.5	7.0	10.1	-22.1	6.6	-4.1	+3.4%
2016	-13.3	-6.6	5.8	20.8	10.2	-10.4	8.5	-7.8	2.2	-1.9	10.9	-4.1	+8.9%
2015	-3.4	12.7	2.9	-3.0	17.7	1.5	12.9	-0.5	-5.8	23.0	13.0	-1.3	+88.7%
2014	10.5	-10.5	-3.1	-4.6	2.4	-2.1	56.0	2.9	-2.3	8.4	-25.0	-1.7	+15.2%
2013	14.9	17.2	17.7	-4.8	-4.8	11.8	-28.6	-23.9	38.9	21.3	-3.8	3.4	+46.0%
2012	25.0	-4.6	1.2	0.6	0.0	0.0	21.2	36.9	6.7	-8.6	3.3	-12.7	+77.1%
2011	20.0	-13.5	1.5	8.0	-4.1	-8.5	11.5	-20.7	-8.7	27.6	1.5	2.9	+7.7%
2010	-2.7	-6.8	2.9	0.0	3.6	-12.4	-9.4	-9.6	4.8	10.1	5.8	2.4	−13.3%
2009	8.2	27.3	20.2	25.7	3.1	2.3	37.3	-13.0	8.1	-2.3	-10.1	-1.3	+145.9%
2008	-4.6	-17.5	20.0	-15.7	51.2	-7.7	-20.8	3.2	0.0	-19.4	-10.1	-14.1	−43.5%
2007	8.0	-6.2	8.6	-6.1	8.4	-3.6	-25.9	3.3	3.2	7.8	-16.7	-6.1	−28.0%

INSD

Insider Activity · NEO

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

234.1K shares

Sells, 6 months

30.6K shares

Net shares

+203.5K

Net change in insider shares

+8.10%

Date	Insider	Transaction	Shares	Value
Sep 30, 2026	Stone WarrenPresident	—	17.6K	—
Aug 20, 2026	Stone WarrenPresident	—	28.1K	—
Aug 3, 2026	Aunan Gregory DOfficer	Sale at price 16.07 per share.	20K	$321.40K
Jun 14, 2026	Tetrault Lynn A.Director	Sale at price 11.10 per share.	5.3K	$58.91K
Jun 8, 2026	Tetrault Lynn A.Director	Sale at price 11.29 per share.	5.3K	$59.92K
May 31, 2026	Perez David BrianDirector	—	23.1K	—
May 31, 2026	Kelly Michael AaronDirector	—	23.1K	—
May 31, 2026	Gunn NeilDirector	—	23.1K	—
May 31, 2026	Green Marjorie CDirector	—	23K	—
May 31, 2026	Tetrault Lynn A.Director	—	23.1K	—
May 31, 2026	Williams FeliciaDirector	—	23.1K	—
May 31, 2026	Kanovsky Stephen MichaelDirector	—	23.1K	—
May 31, 2026	Kenny John PDirector	—	5.9K	—
May 10, 2026	Olivo Alicia CGeneral Counsel	—	3.9K	—
May 10, 2026	Stone WarrenPresident	—	5.8K	—
Apr 30, 2026	Stone WarrenPresident	—	6K	—
Apr 30, 2026	Aunan Gregory DOfficer	—	5.4K	—
Mar 31, 2026	Stone WarrenPresident	—	17.6K	—
Mar 31, 2026	Zook Anthony PChief Executive Officer	—	140.5K	—
Feb 22, 2026	Olivo Alicia CGeneral Counsel	—	29.5K	—

CONG

Congress Trades · NEO

House reports since 2025

Members

1 last bought

Buys

~$16.0K

Sells

~$0

Net

+$16.0K

est. bought − sold

Latest

Aug 7, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	2		+$16.0K	Bought Aug 7, 26

Bought and sold by quarter (est.)

House members' NEO trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Aug 7, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Sep 10, 26 (34d)	PDF
May 7, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Jun 6, 25 (30d)	PDF

From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

NEO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

NEO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NeoGenomics, Inc.

Seasonality · NEO

Insider Activity · NEO

Congress Trades · NEO

Members who traded it

Bought and sold by quarter (est.)

Congress Trades · NEO

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · NEO

Seasonality · NEO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NeoGenomics, Inc.

Financial Snapshot

Earnings & Dividends

News